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patients. However, because VOD is a rather rare dis-
ease, to confirm our results it is necessary to enrol
many more patients in a multicenter study.REFERENCES
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Age and Total-Body
Irradiation in Addition to
Corticosteroid Dose Are
Important Risk Factors for
Avascular Necrosis of the Bone
This report by McAvoy et al. [1] highlights impor-
tant aspects of the risk factors for the development of
avascular necrosis (AVN) of the bone after hematopoi-
etic cell transplantation (HCT). They show a clear
relationship between steroid exposure and impact of
steroid dose on the risk of developing AVN.Our group
has recently presented data of a retrospective case-
control study [2] and found some important differencescompared toMcAvoy’s findings.We analyzed a variety
of known risk factors in a cohort of patients (cases, 50;
controls, 156) without a pretransplant diagnosis of
AVN undergoing allogeneic HCT (allo-HCT) from
a human leukocyte antigen (HLA)-identical related
donor (n 5 133) or HLA-matched unrelated donor
(n 5 65) or umbilical cord HCT (n 5 6) after either
ablative (n5 142) or reduced-intensity (n5 64) prepar-
ative regimens. Median time from transplant to AVN
diagnosis was 1.2 years (range: 0.12-5.2). Median
follow-up was 3.7 years (range: 0.2-8.6) for AVN
patients versus 1.9 years (range: 0.3-9.0) for controls
(P\ .001). Patients with AVNwere significantly youn-
ger than controls at time of transplant (median age 37
versus 48 years, P \ .001) and were more likely to
have a history of tobacco use (68% versus 43%, P 5
.012). In univariate analyses, unrelated donor (48% of
AVN patients versus 30% of controls, P 5 .043), use
of total-body irradiation (TBI) (irrespective of dose)
in preparative regimens (72% versus 46%, P 5 .001),
and systemic steroids (SS) to treat graft-versus-host
disease (GVHD) (98% versus 84%, P5 .009) were as-
sociatedwith increased risk of AVN.Mean peak dose of
SS was higher in the AVN patients versus controls (1.6
versus 1.4mg/kg/day prednisone equivalent,P5 .014).
The median duration of SS treatment prior to AVN
diagnosis was 228 days (range: 104-400), and 60% of
these patients were receiving SS at the time of AVN
diagnosis. Median total duration of SS therapy in
patients with AVN was 712 days (range: 293-1195)
and was significantly longer compared with the control
cohort (383 days; range: 38-630) (P\ .001). Interest-
ingly, this association was seen only in patients age
.40 years (AVN versus control; 852 days [range:
591-1616] versus 416 days [range: 15-596], P\ .001].
The finding of steroid exposure and dose relationship
(function of dose and duration) was similar to what
was seen in the McAvoy study, although duration of
steroid use was not specifically addressed. There were
no significant differences in ethnicity, gender, diagno-
sis, disease status, bodymass index (BMI), bone density,
incidence or severity of GVHD, or survival between
the AVN and control patients. Inmultivariate analyses,
age (\40 years; odds ratio [OR]5 2.55, P5 .008), TBI
(OR5 2.29, P5 .027), and SS (.1 mg/kg/day; OR5
3.48, P5 0.052) were independent predictors of AVN.
Our study identifies the use of TBI in preparative
regimens as a risk factor for development of AVN.
This factor was not identified in the McAvoy study,
but has been previously reported [3]. In our study,
age \40 years was associated with a higher risk of
AVN, and is an important observation and differs
from previous study, where older age has been associ-
ated with AVN [4]. The McAvoy study was controlled
for age between cases and controls and thus could not
address this. Pretransplant smoking was identified as
a significant factor in univariate analyses and has
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in a nontransplant population without steroid use [5].
Our study confirms the impact of steroid use,
including duration of steroid as a risk factor for AVN af-
ter allo-HCT, and further identifies younger age and use
ofTBI inpreparative regimens as important associations.
The finding of a high rate of AVN in long-term young
survivors after allo-HCT who are mostly cured of their
underlying disease and have few comorbidities is of
concern.Themechanismbywhich age influences the in-
cidence of AVN after allo-HCT remains unknown and
may involve hormonal status, bone physiology, or yet
unidentified genetic susceptibilities. Our data and the
report from McAvoy et al. emphasize the need for early
therapeutic interventions to prevent disabling long-
termcomplications and close follow-up inhigh-riskpop-
ulations for AVN in an effort to improve quality of life.
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